ROUTINE & CUSTOM TESTING
Specialty Capabilities
Let's Get Started
Alcami Biologics
Analytical Services
Manufacturing
Support Services
Company Overview
News & Media
Events
Join Our Team
By: Alcami Sep 17, 2019 11:15:14 AM
Biosimilars are sometimes incorrectly considered equivalent to a generic small molecule therapeutic, but for a biologic drug product, the clinical and regulatory pathways are quite different. Alcami Commercial Development Manager Cheryl Johnson explains the distinct differences in the FDA’s definition, development strategy, and regulatory approval pathways.